Aura Biosciences, Inc.
No enriched coverage for $AURA in the last 7 days.
No SEC Form 4 filings for $AURA in the last 30 days.
See all $AURA insider activity →Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
H.C. Wainwright cut its price target for Aura Biosciences (NASDAQ:AURA) to $18 from $24 and kept a Buy rating. The stock trades at about $8.04. The firm cited Phase 3 CoMpass enrollment completion in June 2026 (108 patients) and expects topline data in 2H 2027, while shifting capital toward ocular oncology.
Aura Biosciences, Inc. (AURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on develo
Recent AURA coverage spans financial news, corporate actions and earnings.
Workforce reduction signals cost control and runway extension, which can stabilize sentiment but may raise execution risk concerns.
The analyst PT cut signals reduced valuation confidence, but the maintained Buy and ongoing Phase 3 enrollment progress may limit downside.
Clinical execution and cash runway extension are the key near-term drivers for AURA, with NMIBC deprioritization reallocating risk toward ocular oncology.
Authorized-share expansion can increase future dilution capacity, which may pressure valuation until paired with a clear capital plan.
Near-term catalyst is execution progress toward BFS completion and pilot plant commissioning, with funding discussions tied to the finalized flowsheet.
alphai scores every news story that mentions AURA with an AI model for sentiment and relevance, and aggregates insider trades from Aura Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readH.C. Wainwright cut its price target for Aura Biosciences (NASDAQ:AURA) to $18 from $24 and kept a Buy rating. The stock trades at about $8.04. The firm cited Phase 3 CoMpass enrollment completion in June 2026 (108 patients) and expects topline data in 2H 2027, while shifting capital toward ocular oncology.
3 min readAura Biosciences, Inc. (AURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on develo
6 min readAura Biosciences, Inc. (AURA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 5, 2026, Aura Biosciences, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). As of June 12, 2026, the record date for the Special Meeting, there were 103,436,416 shares of
2 min read31 July 2026 Activities Report for June Quarter 2026 Aura Energy Limited (ASX: AEE, AIM: AURA) ("Aura" or the "Company") is pleased to provide its activities report for the quarter ended 30 June 2026.
4 min readAura Power said North Somerset Council granted planning permission for a 100MW/400MWh, 4-hour BESS in Sandford, with grid connection via existing National Grid infrastructure. The company plans to work with National Grid to advance the connection date amid UK network reforms. Aura also has a 4-hour BESS under construction in Cheshire and targets 1GW RTB solar and storage by 2028.
4 min readGreentechLead reports renewable-energy updates. Masdar reached financial close on a $6.1B Abu Dhabi 24/7 solar plus battery project, with 5.2 GW PV and 19 GWh storage, targeting 1 GW continuous output. Aura Power received UK planning approval for a 100 MW, four-hour Sandford BESS. NextEnergy’s Starlight got consent for a 240 MW/960 MWh UK BESS.
2 min readAura Biosciences (NASDAQ: AURA) said it appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors. The company noted Bender’s prior leadership at Day One Biopharmaceuticals and experience in oncology development and commercialization. Aura also referenced Phase 3 CoMpass trial enrollment completion and bel-sar’s potential regulatory approval path.
2 min readAura Biosciences, Inc. (AURA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001501796 false 0001501796 2026-07-03 2026-07-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2
2 min readBiotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG
7 min read
